203: Right Ventricular Failure (RVF) in Patients with Continuous Flow Left Ventricular Assist Devices (LVAD)

Kormos, Robert L.; Teuteberg, J.; Russell, Stuart D.; Massey, Todd; Feldman, David S.; Moazami, Nader; Farrar, David J.; Milano, Carmelo A.

doi:10.1016/j.healun.2007.11.211

Search citation statements

Order By: Relevance

Paper Sections

Select...

Selection and Risk Scores With Focus On Right Ventricular Fa1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2013

Publication Types

Select...

Article1

Book1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interpretation of these data is clouded by the fact that most publications identified only univariate predictors and describe exclusively18,39,69,71–73,76,78,92 or mostly first generation devices 19,65. Although RV failure appears less common with second generation devices,28,30 there are also fewer parameters to predict it 94…”

Section: Selection and Risk Scores With Focus On Right Ventricular Famentioning

confidence: 99%

Patient selection for left ventricular assist devices

Lund

Cowger

Aaronson

2010

European J of Heart Fail

155

105

View full text Add to dashboard Cite

Heart transplantation (HTx) improves symptoms and prolongs life in advanced heart failure (HF), but organ supply is limited. In recent years, mechanical circulatory support and specifically implantable left ventricular assist devices (LVADs) have undergone technical improvements, and outcomes have improved dramatically. Left ventricular assist devices are now viable options for patients with severe HF as bridge to transplantation, destination therapy, or as bridge to recovery. Many believe that LVADs may soon provide outcomes similar to, or better than, HTx, launching a new era of end‐stage HF management. The key to improving outcomes is patient selection, but the field is changing rapidly and guidelines and consensus are limited. This review summarizes recent reports of predictors of poor outcomes and provides an overview of selection for LVAD therapy.

show abstract